Patkowska E, Krzywdzinska A, Solarska I, Wojtas M, Prochorec-Sobieszek M
Curr Issues Mol Biol. 2025; 47(2).
PMID: 39996833
PMC: 11853749.
DOI: 10.3390/cimb47020111.
Diamantidis M
J Clin Med. 2024; 13(20).
PMID: 39458104
PMC: 11509401.
DOI: 10.3390/jcm13206154.
Mao M, Deng S
Oncol Lett. 2024; 28(1):324.
PMID: 38807682
PMC: 11130743.
DOI: 10.3892/ol.2024.14458.
Loscocco G, Vannucchi A
Ann Hematol. 2023; 102(8):1973-1984.
PMID: 37286874
PMC: 10345021.
DOI: 10.1007/s00277-023-05288-1.
Yang Y, Shu Y, Tang Y, Zhao S, Jia Y, Ji J
Cancer Med. 2023; 12(8):9156-9166.
PMID: 36916780
PMC: 10166975.
DOI: 10.1002/cam4.5654.
Extramedullary Myeloid Leukemia in the Setting of a Myeloproliferative Neoplasm.
Kosti J, Mervak T, Terebelo H
J Med Cases. 2022; 13(11):561-568.
PMID: 36506761
PMC: 9728152.
DOI: 10.14740/jmc3996.
Hoxa11-mediated reduction of cell migration contributes to myeloid sarcoma formation induced by cooperation of MLL/AF10 with activating KRAS mutation in a mouse transplantation model: Hoxa11 in myeloid sarcoma formation.
Fu J, Wen C, Yen T, Shih L
Neoplasia. 2022; 29:100802.
PMID: 35500545
PMC: 9065885.
DOI: 10.1016/j.neo.2022.100802.
Extramedullary acute myeloid leukemia (eAML): Retrospective single center cohort study on clinico-pathological, molecular analysis and survival outcomes.
Halahleh K, Alhalaseh Y, Al-Rimawi D, Dana W, Alrabi K, Kamal N
Ann Med Surg (Lond). 2021; 72:102894.
PMID: 34815855
PMC: 8593591.
DOI: 10.1016/j.amsu.2021.102894.
An isolated childhood myeloid sarcoma with germline MSH6 mutation-a case report.
Liu Y, GuLiBaHa M, Yue Y, Li M, Cao S, Yan M
Transl Pediatr. 2021; 10(8):2136-2143.
PMID: 34584885
PMC: 8429872.
DOI: 10.21037/tp-21-326.
A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study.
Wang X, Zhang L, Zhou D, Cai H, Wang X, Jiang X
Medicine (Baltimore). 2020; 99(50):e21948.
PMID: 33327223
PMC: 7738061.
DOI: 10.1097/MD.0000000000021948.
Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow.
Engel N, Reinert J, Borchert N, Panagiota V, Gabdoulline R, Thol F
Ann Hematol. 2020; 100(2):499-503.
PMID: 33108522
PMC: 7817572.
DOI: 10.1007/s00277-020-04313-x.
Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Jutzi J, Basu T, Pellmann M, Kaiser S, Steinemann D, Sanders M
Blood. 2019; 133(16):1766-1777.
PMID: 30755419
PMC: 6484461.
DOI: 10.1182/blood-2018-09-875047.
RTK-RAS pathway mutation is enriched in myeloid sarcoma.
Choi M, Jeon Y, Sun C, Yun H, Hong J, Shin D
Blood Cancer J. 2018; 8(5):43.
PMID: 29789584
PMC: 5964090.
DOI: 10.1038/s41408-018-0083-6.
Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.
Caraffini V, Perfler B, Berg J, Uhl B, Schauer S, Kashofer K
Blood. 2018; 131(7):826-830.
PMID: 29295844
PMC: 5824335.
DOI: 10.1182/blood-2017-09-804906.
Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.
Kashofer K, Gornicec M, Lind K, Caraffini V, Schauer S, Beham-Schmid C
Leuk Lymphoma. 2017; 59(2):501-504.
PMID: 28633614
PMC: 5743000.
DOI: 10.1080/10428194.2017.1339879.
